The effectiveness of switching to Tiotropium / Olodaterol combination in patients with COPD

The effectiveness of switching to Tiotropium / Olodaterol combination in patients with COPD - The effectiveness of switching to Tiotropium / Olodaterol combination

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025049

Enrollment

Registered

2016-12-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Switching from Glycopirronium / Indacaterol or Umeclidinium / Vilanterol to Tiotropium / Olodaterol combination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Diagnosis of moderate-to-severe COPD. -Post-bronchodilator FEV1/FVC < 70%. -Post bronchodilator FEV1 < 80% predicted normal. -Smoking history of 10 pack-years or more. -Patients treated with Glycopirronium / Indacaterol or Umeclidinium / Vilanterol to Tiotropium / Olodaterol.

Exclusion criteria

Exclusion criteria: -Patients with a history of asthma. -Patients who are already treated with ICS or oral corticosteroid regularly. -Patients who have experienced a COPD exacerbation within the previous 8 weeks. -Patients with uncontrolled cardiac diseases.

Design outcomes

Primary

Measure	Time frame
Change in FEV1 between week 0 and week 8	—

Secondary

Measure	Time frame
Change in FVC between week 0 and week 8 Change in FOT parameters between week 0 and week 8 Change in CAT between week 0 and week 8 Change in mMRC between week 0 and week 8	—

Countries

Japan

Contacts

Public ContactTaisuke Akamatsu

Shizuoka General Hospital Department of Respiratory Medicine

taisuke-akamatsu@i.shizuoka-pho.jp054-247-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026